Preparation and Evaluation of Inflammation Targeted Nano-micellar Formulation of Celecoxib

Celecoxib
DOI: 10.14235/bas.galenos.2018.2673 Publication Date: 2019-07-26T08:21:26Z
ABSTRACT
Objective: Celecoxib (CLX), brand named Celebrex, which belongs to non-steroidal anti-inflammatory drugs family, selectively inhibits the cytokine related cyclooxygenase-2 isoenzyme and thus, possesses less gastrointestinal side effects, have shown cause stroke, myocard infarction even death in some cases.In this study we aimed target inflammation site using CLX uploaded nano-micelles (nano-CLX) made of poly (lactic-co-glycolic) acid (PLGA) protect other tissues from its effects.Methods: was physically entrapped PLGA micelles w/o/w emulsion method, resulted obtaining mono-dispersed particles with 112 nm size.50 mg able carry 50 20 mL (2.5 mg/mL) encapsulation efficiency 85%.Rheumatoid arthritis model achieved by injection complete Freund's Adjuvant hint paw Wistar rats.Infected groups received oral intravenous (i.v.) Celebrex nano-CLX.Each group compared a healthy control receiving drug via same routes.The obtained serums sizes were studied for 6 hours 3 time periods.Results: Prostaglandin E2 tumor necrosis factor-α levels found be decreased longer period application nano-CLX i.v.Celebrex.Interleukin-1 (IL-1) IL-6 showed dramatic decrease at orally administered groups, showing accumulation these pro-inflammatory factors area. Conclusion:Based on hypothesis that ratio blood parameters is inversely proportional site, our nano-formulation targeted systemic flow better selective inhibition.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (3)